loading page

In a real-life setting, direct-acting antivirals to people who inject drugs with chronic hepatitis C in Turkey
  • +41
  • Figen Sarigul,
  • Ülkü Üser,
  • Didem Sarı,
  • Behice Kurtaran,
  • Yusuf Önlen,
  • Ebubekir Senates,
  • Alper Gündüz,
  • Esra Zerdali,
  • Hasan Karsen,
  • AYŞE BATIREL,
  • Ritvan Karali,
  • Rahmet Güner,
  • Tansu Yamazhan,
  • Sukran Kose,
  • Nurettin Erben,
  • Nevin İnce,
  • Iftihar Koksal,
  • Nefise Oztoprak,
  • GÜLŞEN YÖRÜK,
  • Süheyla Kömür,
  • Tayibe Bal,
  • Sibel Yıldız Kaya,
  • ilkay bozkurt,
  • ÖZGÜR GÜNAL,
  • İlknur Esen Yıldız,
  • Dilara Inan,
  • Şener Barut,
  • Mustafa Namiduru,
  • Selma Tosun,
  • Kamuran Türker,
  • Alper Şener,
  • Kenan Hizel,
  • Nurcan Baykam,
  • Fazilet Duygu,
  • Hurrem Bodur,
  • Güray Can,
  • Hanefi Cem Gül,
  • Ayşe SAĞMAK TARTAR,
  • Guven Celebi,
  • Mahmut Sünnetci,
  • Oguz Karabay,
  • Hayat Kumbasar,
  • Fatma Sırmatel,
  • Fehmi Tabak
Figen Sarigul

Corresponding Author:drfigensarigul@yahoo.com.tr

Author Profile
Ülkü Üser
Author Profile
Didem Sarı
Istanbul Training and Research Hospital, Infectious Diseases
Author Profile
Behice Kurtaran
Author Profile
Yusuf Önlen
Author Profile
Ebubekir Senates
Medeniyet Universitesi Goztepe Egitim ve Arastirma Hastanesi
Author Profile
Alper Gündüz
Author Profile
Esra Zerdali
Author Profile
Hasan Karsen
Harran University School of Medicine
Author Profile
AYŞE BATIREL
Author Profile
Ritvan Karali
Istanbul Universitesi-Cerrahpasa
Author Profile
Rahmet Güner
Ankara Yildirim Beyazit University Faculty of Medicine
Author Profile
Tansu Yamazhan
Author Profile
Sukran Kose
Ministry of Health Tepecik Hospital, Infectious Diseases Clinic
Author Profile
Nurettin Erben
Author Profile
Nevin İnce
Duzce Universitesi
Author Profile
Iftihar Koksal
Karadeniz Technical University
Author Profile
Nefise Oztoprak
Zonguldak Karaelmas University
Author Profile
GÜLŞEN YÖRÜK
Author Profile
Süheyla Kömür
Author Profile
Tayibe Bal
Mustafa Kemal Universitesi Tayfur Ata Sokmen Tip Fakultesi
Author Profile
Sibel Yıldız Kaya
Sungurlu State Hospital
Author Profile
ilkay bozkurt
Author Profile
ÖZGÜR GÜNAL
Author Profile
İlknur Esen Yıldız
Recep Tayyip Erdogan University Training and Research Hospital
Author Profile
Dilara Inan
Akdeniz University Faculty of Medicine
Author Profile
Şener Barut
Author Profile
Mustafa Namiduru
Author Profile
Selma Tosun
University of Health Sciences Izmir Bozyaka Education and Research Hospital
Author Profile
Kamuran Türker
Author Profile
Alper Şener
Author Profile
Kenan Hizel
Author Profile
Nurcan Baykam
Hitit University
Author Profile
Fazilet Duygu
Author Profile
Hurrem Bodur
Saglik Bilimleri Universitesi
Author Profile
Güray Can
Author Profile
Hanefi Cem Gül
Author Profile
Ayşe SAĞMAK TARTAR
Firat University, Faculty of Medicine
Author Profile
Guven Celebi
Zonguldak Karaelmas University
Author Profile
Mahmut Sünnetci
Author Profile
Oguz Karabay
Sakarya University
Author Profile
Hayat Kumbasar
Author Profile
Fatma Sırmatel
Author Profile
Fehmi Tabak
Istanbul University-Cerrahpasa Cerrahpasa Faculty of Medicine
Author Profile

Abstract

Introduction: People who inject drugs (PWID) should be treated in order to eliminate hepatitis C virus (HCV) in the world. Aims: The aim of this study was to compare direct acting antivirals (DAAs) treatment of HCV for PWID and non-PWID in real life setting. Materials and methods: We performed a prospective, non-randomized, observational multi-center cohort study in 37 centers. All patients treated with DAAs therapy between April 1, 2017 to February 28, 2019 were included. In total, 2,713 patients were included in the study among which 250 were PWID and 2,463 were non-PWID. Besides patient characteristics, treatment response, follow-up and side effects of treatment were also analyzed. Results: Genotype 1a and 3 were more prevalent in PWID infected patients (20.4% vs 9.9% and 46.8% vs 5.3%). The number of naïve patients was higher in PWID (90.7% vs 60.0%), while the number of patients with cirrhosis was higher in non-PWID (14.1% vs 3.7%). The loss of follow up was higher in PWID (29.6% vs 13.6%). There was no difference in the sustained virologic response at 12 weeks after treatment (98.3% vs 98.4%), but the end of treatment response was lower in PWID (96.2% vs 99.0%). In addition, the rate of treatment completion was lower in PWID (74% vs 94.4%). Conclusion: DAAs were safe and effective in PWID. Primary measures should be taken to prevent the loss of follow-up and poor adherence in PWID patients in order to achieve World Health Organization’s objective of eliminating viral hepatitis.